Study helps eliminate causes for joint pain linked to commonly used breast cancer drugs

	Tweet

Researchers exploring why some women who take a common breast cancer drug develop serious joint pain have eliminated two possible causes: inflammatory arthritis and autoimmune disease. Because of these findings, researchers say women should be encouraged to continue taking the medication to gain its full benefit.

The study is published online Nov. 11 in the journal Breast Cancer Research and Treatment. Preliminary findings were presented in 2010 at the 74th Annual Scientific Meeting of the American College of Rheumatology.

For many post-menopausal women with breast cancer promoted by the hormone estrogen, aromatase inhibitors (AI) can dramatically reduce the risk of their cancer coming back. Doctors say the AIs must be taken for five years to gain the full benefit, however, the development of joint complaints in up to 35 percent of women forces many of them to stop early out of concern that the pain signals a more serious condition.

"It’s not clear why joint symptoms occur with AI use, but we wondered if it could be related to inflammation or an autoimmune disease,” says rheumatologist Victoria K Shanmugam, MBBS, MRCP, assistant professor of medicine at Georgetown University Medical Center, and the study’s lead author. “Our research ruled out both.”

Forty-eight postmenopausal women with state I, II or III breast cancer treated at Georgetown Lombardi Comprehensive Cancer Center were invited to take part in the study. All had hand pain and no known autoimmune disease. Of them, 25 women were taking AIs; 23 women were not taking AIs.

Subjects were evaluated after abstaining from non-steroidal anti-inflammatory drugs for 48 hours. Signs of inflammation from arthritis would reappear in that time frame, the researchers reasoned. All the women completed a health assessment questionnaire. The rheumatologist conducted a personal history and physical examination with each patient. Various blood tests were conducted and x-rays and ultrasounds of all participants’ hands were performed. The rheumatologist and radiologist did not know which participants were taking AIs and which were not.

“We found that several patients in the control arm had a similar constellation of symptoms to those receiving AIs, but our team did not find any conclusive evidence that women taking AIs were more likely to have inflammatory arthritis or an autoimmune disease,” Shanmugam says.

An autoimmune disease was discovered in four of the 48 women – two in each group—that had previously been undiagnosed. The cases were equally distributed among cases and controls.

“It would be prudent to refer those experiencing joint pain to a rheumatologist to rule out a previously undiagnosed autoimmune disease, and so that we can help address the symptoms,” Shanmugam says.

“Although our study helps to rule out inflammatory arthritis or autoimmune disease as cause for joint pain associated with AIs, we still do not know why these women have musculoskeletal symptoms. Since the syndrome doesn’t appear to be related to inflammatory arthritis or autoimmune disease, women should be encouraged to stay on their medication so they can gain the full benefit from it.”
###

The authors report no related financial interests. This work was supported by a development grant from the Georgetown University Hospital Department of Internal Medicine, and by the Swing Fore the Cure Foundation. Shanmugam was supported by the Physician Scientist Development Award from the American College of Rheumatology Research and Education Foundation and is currently supported awards from the National Center for Research Resources at National Institutes of Health. In addition, Shanmugam is supported by a KL2 Mentored Career Development Program Scholar grant from Georgetown-Howard Universities Center for Clinical & Translational Science.

About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis—or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university’s sponsored research funding.

###

Karen Mallet

Georgetown University Medical Center

RELATED STORIES:
Breast cancer screening may fuel over diagnosis   Adapting Space-Industry Technology to Treat Breast Cancer   Breast Cancer Impact on Same Sex Couples   One-in-five women would consider breast removal   Soy reduces breast cancer risk by receptor status   Menopause drug Livial ups breast cancer return risk   Study confirms breast cancer worse in US blacks   A novel therapeutic target to slow breast cancer cell motility   Strenuous exercise lowers lifetime breast cancer risk   Ethnic gaps in breast cancer linked to hormones   Bitter melon extract attacks breast cancer cells   Fish oil may cut breast cancer risk ‘by a third’   Breast Implants Are Most Popular Form of Plastic Surgery   Untangling the development of breast cancer   Reflexology helps women with breast cancer cope   Breast Brachytherapy Use Outpaces Evidence   City-dwelling women at greater risk for breast cancer   New study suggests Concord grape juice may provide protection against breast cancer   Radiation rates for breast cancer may be underestimated, U-M study finds   Breast cancer radiotherapy gentler on the heart   Drug combo ups breast cancer survival-study   UCSF team discovers new way to predict breast cancer survival and enhance effectiveness of treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]